

RoL nr 233 December 2021

Hur man blir av med läkemedel ...

1. Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, et al. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUC_i/AUC) ratios. *Drug Metab Dispos Biol Fate Chem*. 2004 Nov;32(11):1201–8.
2. Michael Andresen. Tramadol – ett krångligt sätt att ge opioider. [Internet]. Region Örebro län; 2021 [cited 2021 Nov 10]. Available from: <https://vardgivare.regionorebrolan.se/siteassets/media/varrdiktlinjer/lakemedelscentrum/rapport-om-lakemedel/2021/nummer-229-februari-2021.web.pdf>
3. McDonnell AM, Dang CH. Basic Review of the Cytochrome P450 System. *J Adv Pract Oncol*. 2013;4(4):263–8.
4. Absorption av järn i tablettform. [Internet]. Läkemedelscentrum Region Örebro län; 2021 [cited 2021 Nov 2]. Available from: https://vardgivare.regionorebrolan.se/contentassets/c71318ba4595421798c3b92355c9a2b4/rapport-nr-232_210909_tillganglig_2.pdf
5. GENEVESTIGATOR Team at Nebion AG. Genevisible [Internet]. [cited 2021 Nov 4]. Available from: <https://genevisible.com>
6. Michael Andresen. Paracetamolöverdos – när enzym blir mätta... [Internet]. Region Örebro län; 2021. Available from: <https://vardgivare.regionorebrolan.se/siteassets/media/varrdiktlinjer/lakemedelscentrum/rapport-om-lakemedel/2021/rapport-nr-230.webb.pdf>
7. Vázquez M, Maldonado C, Guevara N, Rey A, Fagiolino P, Carozzi A, et al. Lamotrigine-Valproic Acid Interaction Leading to Stevens–Johnson Syndrome. *Case Rep Med*. 2018 Aug 29;2018:e5371854

CLINT-fråga: Finns det rekommendationer hur dosering av lisdexamfetamin (Elvanse) kan anpassas utifrån genetiska variationer i dess metabolism?

1. Elvanse - FASS Vårdpersonal [Internet]. [cited 2021 Oct 20]. Available from: <https://www.fass.se/LIF/product?userType=0&nplld=20140730000117>
2. PubChem. Lisdexamfetamine [Internet]. [cited 2021 Oct 20]. Available from: <https://pubchem.ncbi.nlm.nih.gov/compound/11597698>

3. Adler LA, Alperin S, Leon T, Faraone SV. Pharmacokinetic and Pharmacodynamic Properties of Lisdexamfetamine in Adults with Attention-Deficit/Hyperactivity Disorder. *J Child Adolesc Psychopharmacol*. 2017 Mar;27(2):196–9.
4. Roberts JK, Cook SF, Stockmann C, Rollins DE, Wilkins DG, Sherwin CMT. A Population Pharmacokinetic Analysis of Dextroamphetamine in the Plasma and Hair of Healthy Adults. *Clin Drug Investig*. 2015 Oct;35(10):633–43.
5. de la Torre R, Farré M, Navarro M, Pacifici R, Zuccaro P, Pichini S. Clinical pharmacokinetics of amphetamine and related substances: monitoring in conventional and non-conventional matrices. *Clin Pharmacokinet*. 2004;43(3):157–85.
6. PharmGKB amphetamine [Internet]. PharmGKB. [cited 2021 Oct 20]. Available from: <https://www.pharmgkb.org/chemical/PA448408/variantAnnotation>
7. Matsusue A, Ikeda T, Tani N, Waters B, Hara K, Kashiwagi M, et al. Association between cytochrome P450 2D6 polymorphisms and body fluid methamphetamine concentrations in Japanese forensic autopsy cases. *Forensic Sci Int*. 2018 Aug;289:33–9.